Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Emerging Insights on Adverse Events During ART and Implications for Treatment: Nephrotoxicity and Long-Acting Injectables

Hear insights and answers to audience questions from Fidelia Bernice, PharmD, and Aadia I. Rana, MD, on HIV ART safety and tolerability including recent data on nephrotoxicity and safety with long-acting injectables.
Fidelia Bernice, PharmD
Aadia I. Rana, MD
Released: November 16, 2021

In this episode, Fidelia Bernice, PharmD, and Aadia I. Rana, MD, share insights on HIV ART safety and tolerability including recent data on nephrotoxicity and the use of NRTI-sparing regimens with discussion of the GEMINI-1 and -2 studies of DTG/3TC and the SWORD-1 and -2 studies of DTG/RPV, and safety with long-acting injectables with specific discussion of the ATLAS and FLAIR studies of LA CAB plus RPV and the CUSTOMIZE study.

Information on this Educational Activity

Faculty

Fidelia Bernice, PharmD

Clinical Pharmacy Specialist, Infectious Diseases
Department of Pharmacy
University of Maryland Medical Center
Baltimore, Maryland

Fidelia Bernice, PharmD, has no relevant conflicts of interest to report.
Aadia I. Rana, MD

Associate Professor of Medicine
Division of Infectious Diseases
University of Alabama at Birmingham
1917 Clinic
Birmingham, Alabama

Aadia I. Rana, MD, has disclosed that she has received funds for research support from Merck.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grant provided by
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

Dr Mark Sulkowski and Clinical Care Options (CCO): Treatment of both HIV and HCV should be prioritized for patients that are coinfected with careful consideration of drug-drug interactions.

Mark S. Sulkowski, MD Released: January 19, 2022

Slides from CCO: Discussion of key data and recommendations for choosing ART regimens for older patients with renal impairment or liver disease.

Jonathan Appelbaum, MD, FACP, AAHIVS Jens D. Lundgren, MD, DMSc Released: January 13, 2022

Clinical Care Options (CCO) presents a woman’s perspective on managing the long-term effects of HIV, antiretroviral therapy, and aging

person default Anonymous Patient Released: January 11, 2022

Clinical Care Options (CCO): woman’s perspective on her struggle with HIV stigma and why volunteering to help others with HIV has become her purpose

person default Anonymous Patient Released: January 10, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings